Effect of IFN-α on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma

Journal of Interferon and Cytokine Research

Volumn 18, Issue 1, 1998, Pages 33-39

  Hakansson A ^a   Gustafsson, B ^a   Krysander, L ^a   Hakansson L ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; INDOMETACIN; MONOCLONAL ANTIBODY CD 11C; OKT 4; OKT 8; RECOMBINANT ALPHA INTERFERON; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL DENSITY; CELL INFILTRATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; MONONUCLEAR CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031881714     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.33     Document Type: Article

References (36)

1. CREAGAN, E.T., SCHAID, D.J., AHMANN, D.L., and FRYTAK, S. (1988). Recombinant interferons in the management of advanced malignant melanoma. Am. J. Clin. Oncol. 11, 652-659.
2. LEGHA, S.S. (1989). Current therapy for malignant melanoma. Semin. Oncol. 16, 34-44.
3. SCHLOM, J., COLCHER, D., HORAN HAND, P., GREINER, J., WUNDERLICH, D., WEEKS, M., FISHER, P.B., NOGUCHI, P., PESTKA, S., and KUFE, D. (1985). Monoclonal antibodies reactive with breast tumor associated antigens. Adv. Cancer Res. 43, 143-173.
4. MURRAY, J.L., and ROSENBLUM, M.G. (1991). Modulation of melanoma antigens by interferons. In: Melanoma Research: Genetics, Growth Factors, Metastases and Antigens. Boston: Kluwer Academic Publishers, pp. 153-167.
5. BALKWILL, F. (1989). Interferons. Lancet 1, 1060-1063.
6. KNOP, J. (1990). Immunologic effects of interferon. J. Invest. Dermatol. 95 (Suppl.), 72S-74S.
7. GRESSER, I. (1990). Biologic effects of interferons. J. Invest. Dermatol. 95 (Suppl.), 66S-71S.
8. HURWTTZ, P.J. (1991). Spontaneous regression of metastatic melanoma. Ann. Plast. Surg. 26, 403-406.
9. JONES, P.C., SZE, L.L., LIU, P.Y., MORTON, D.L., and IRIE, R.F. (1981). Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J. Natl. Cancer Inst. 66, 249-254.
10. ABERSHOLD, P., HYATT, C., JOHNSON, S., HINES, K., KORCAK, L., SANDERS, M., LOTZ, M., TOPALIAN, S., YANG, J., and ROSENBERG, S.A. (1991). Lysis of autologous melanoma cells by tumor infiltrating lymphocytes: association with clinical response. J. Natl. Cancer Inst. 83, 932-937.
11. BALCH, C.M., MURAD, T.M., SOONG, S.-J., INGALS, A.L., HALPERN, N.B., and MADDOX, W.A. (1978). A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann. Surg. 188, 732-742.
12. HANSEN, M.G., and McCARTEN, A.B. (1974). Tumor thicknes and lymphocytic infiltration in malignant melanoma of the head and neck. Am. J. Surg. 128, 557-561.
13. LARSEN, T.E., and GRUDE, T.H. (1978). A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. Acta Pathol. Microbiol. Scand. 86, 523-530.
14. CLARK, W.H., ELDER, D.E., GUERRY, D.P.I.V., BRAITMAN, L.E., TROCK, B.J., SCHULTZ, D., SYNNESTVEDT, M., and HALPERN, A.C. Model predicting survival in stage I melanoma based on tumor progression. (1989). J. Natl. Cancer Inst. 81, 1893-1904.
15. CLEMENTE, C.G., BUFALINO, R., ZURRIDA, S., COLLINI, P., and CASCINELLI, N. (1996). Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77, 1303-1310.
16. McGOVERN, V.J., SHAW, H.M., MILTON, G.W., and FARAGO, G.A. (1981). Lymphocytic infiltration and survival in malignant melanoma. In: Pathology of Malignant Melanoma. A.B. Ackerman (ed.) New York: Masson Publishing, pp. 341-344.
17. TEFANY, F.J., BARNETSON, R.S.T.C., HALLIDAY, G.M., McCARTHY, S.W., and McCARTHY, W.H. (1991). Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J. Invest. Dermatol. 97, 197-202.
18. MIMH, M.C., CLEMENTE, C.G., and CASCINELLI, N. (1996). Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab. Invest. 74, 43-47.
19. HÅKANSSON, A., GUSTAFSSON, B., KRYSANDER, L., and HÅKANSSON, L. (1996). Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon-alpha treatment. Br. J. Cancer 74, 670-676.
20. McGOVERN, V.J. (1975). Spontaneous regression of melanoma. Pathology 7, 91-99.
21. KANG, S., BARNHILL, R.L., MIHM, M.C., and SOBER, A.J. (1993). Histologic regression in malignant melanoma: an interobserver concordance study. J. Cutan. Pathol. 20, 126-129.
22. SONDERGAARD, K., and HOU-JENSEN, K. (1985). Partial regression in thin primary cutaneous malignant melanomas clinical stage I. Virchows Arch. A Pathol. Anat. Histopathol. 408, 241-247.
23. RONAN, S.G., ENG, A.M., BRIELE, H.A., SHIOURA, N.N., and DAS GUPTA, T.K. (1987). Thin malignant melanomas with regression and metastases. Arch. Dermatol. 123, 1326-1330.
24. KIRKWOOD, B.R. (1988). Essentials of Medical Statistics. Oxford: Blackwell Scientific Publications, pp. 102-104.
25. KORNSTEIN, M.J., BROOKS, J.S.J., and ELDER, D.E. (1983). Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi. Cancer Res. 43, 2749-2753.
26. POPPEMA, S., BRÖCKER, E.B., DE LEIJ, L., TERBRACK, D., VISSCHER, T., TER HAAR, A., MACHER, E., THE, T.H., and SORG, C. (1983). In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin. Clin. Exp. Immunol. 51, 77-82.
27. RUITER, D.J., BHAN, A.K., HARRIST, T.J., SOBER, A.J., and MIHM, M.C. (1982). Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J. Immunol. 129, 2808-2815.
28. STROHAL, R., MARBERGER, K., PEHAMBERGER, H., and STINGL, G. (1994). Immunohistological analysis of antimelanoma host responses. Arch. Dermatol. Res. 287, 28-35.
29. + T cells. World J. Surg. 19, 352-358.
30. HUTCHINSON, G.H., HEINEMANN, D., SYMES, M.O., and WILLIAMSON, R.C.N. (1981). Differential immune reactivity of tumour intrinsic and peripheral-blood lymphocytes against autoplastic colorectal carcinoma cells. Br. J. Cancer 44, 396-402.
31. ROSENBERG, S.A., SPIESS, P., and LAFRENIERE, R. (1986). A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233, 1318-1321.
32. VOSE, B.M., and MOORE, M. (1985). Human tumor-infiltrating lymphocytes: a marker of host response. Semin. Hematol. 22, 27-40.
33. MIESCHER, S., WHITESIDE, T.L., CARREL, S., and VON FLIEDNER, V. (1986). Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J. Immunol. 136, 1899-1907.
34. VOSE, B.M., and MOORE, M. (1982). Mitogen responsiveness and inhibitory activity of mesenteric lymph node cells. Cancer Immunol. Immunother. 13, 105-111.
35. ROSENBERG, S.A., PACKARD, B.S., AEBERSHOLD, P.M., SOLOMON, D., TOPALIAN, S.L., TOY, S.T., SIMON, P., LOTZE, M.T., YANG, J.C., SEIPP, C.A., SIMPSON, C., CARTER, C., BOCK, S., SCHWARTZENTRUBER, D., WEI, J.P., and WHITE, D.E. (1988). Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319, 1676-1680.
36. HANH, S., GEHRI, R., and ERB, P. (1995). Mechanism and biological significance of CD4-mediated cytotoxicity. Immunol. Rev. 146, 57-79.